How does DEPLOY track the 2026 da Vinci SureForm gray-reload Class I recall?
DEPLOY tracks the [2026 da Vinci SureForm gray-reload Class I recall](https://registry.deploy.report/incidents/davinci-sureform-gray-reload-recall-death-2026) at primary-source-anchored FDA-recall-database verification depth as the surgical cohort's most severe verified incident. The substrate: 8mm SureForm 30 Gray reloads (2mm staples for extra-thin tissue) produced incomplete staple lines on blood vessels despite a 'completed' fire indication; customer letter / quarantine March 11, 2026; FDA classified Class I (reported May 2026); 1 death + 4 serious injuries (bleeding). Blue/white reloads UNAFFECTED at canonical within-product-family verification scope distinction. The framework reads the incident at four substrate layers simultaneously: incident-recall actuarial depth per Phase 3 Dim 1 (severity=critical at primary-source-anchored verification; cohort's most severe); within-entity verification scope at sub-product-line granularity (gray vs blue/white reload distinction is the within-da-Vinci feature-level verification posture distinct); regulatory clearance per jurisdiction at Dim 4 (FDA Class I primary-government-record sub-tier verification); year-discipline framework distinguishing the 2026 gray-reload recall from the 2022 SureForm fragment recall (Z-0340-2023; Class II; October 7, 2022) at year-class-failure-mode granularity. Cap-flag honest-absence at exact recall Z-number + unit count (not captured from primary FDA pages). Root cause stated 'still under investigation' at primary-source-anchored verification depth.
1 death + 4 serious
Patient impact at primary-source FDA-recall-database verification depth
FDA Class I
Most severe FDA recall classification; reported May 2026
March 11 2026
Customer letter / quarantine date at primary-source-anchored verification
Gray reloads affected
8mm SureForm 30 Gray; blue/white UNAFFECTED (within-product-family scope)
Z-number absent
Exact Z-number + unit count cap-flag honest-absence at primary FDA pages
Mid-2026
Snapshot date
The incident at primary-source-anchored verification depth
Per Agent A's surgical incidents substrate, the 2026 da Vinci SureForm gray-reload Class I recall operates at primary-source FDA-recall-database verification depth. The verified substrate:
- Product affected: 8mm SureForm 30 Gray reloads (2mm staples for extra-thin tissue). Blue/white reloads UNAFFECTED at verified-by-disclosure primary-source verification depth.
- Failure mode: incomplete staple lines on blood vessels despite a 'completed' fire indication.
- Customer notification: customer letter and quarantine instruction issued March 11, 2026.
- FDA classification: Class I (reported May 2026); the most severe FDA recall classification (reasonable probability of serious adverse health consequences or death).
- Patient impact: 1 death + 4 serious injuries (bleeding).
- Root cause: stated 'still under investigation' at primary-source verification posture; no root-cause-determined disclosure at primary-source depth.
The framework reads the incident at the verification depth where each fact actually resolves: the product distinction (gray vs blue/white), the failure mode, the customer notification date, the FDA classification, and the patient impact all operate at primary-source FDA-recall-database verification depth. The root cause operates at honest-absence cap-flag depth pending further FDA primary-source verification.
Cohort's most severe incident: Phase 3 Dim 1 actuarial signal canonical worked example
The 2026 SureForm gray-reload incident operates as the canonical actuarial signal at Phase 3 Dim 1 (deployment-incident-recall actuarial depth) per DEPLOY's robot insurance methodology pillar. The verified-base substrate per the four-dimension framework: 61 incidents at primary-source severity + root-cause + regulatory-action depth; severity spread (moderate 21, serious 20, minor 13, critical 7); the 2026 gray-reload incident operates within the 7-critical severity tier.
Per the actuarial framework, the incident operates as the cohort's most severe verified incident at three composing layers:
- Severity: critical at primary-source-anchored verification depth; one death + four serious injuries at typed-record-disclosure depth.
- Regulatory action: FDA Class I primary-government-record sub-tier verification per the 9-tier source-quality rubric; Class I is the most severe FDA recall classification.
- Form factor: surgical; the surgical cohort carries 11 of the 61 verified incidents at Agent A substrate-completeness depth; the 2026 gray-reload incident is the cohort's most severe at primary-source-anchored verification within the surgical form factor.
Per the robot insurance methodology pillar's canonical discipline, honest "insurability unknown for this region / no exposure data" beats fabricated rate. The framework reads the incident at the verified numerator depth (1 death + 4 serious injuries verified at primary-source FDA-recall-database) while the exposure denominator operates at honest-absence cap-flag (no deployment-hours / units-in-service / vessels-stapled data published at the deployment-tier specific to gray-reload usage). The framework does not infer a rate-per-deployment-hour from incident count alone; rate derivation operates only where exposure substrate exists.
Within-entity verification scope: gray vs blue/white reload distinction
The 2026 SureForm gray-reload incident operates as canonical worked example for DEPLOY's verified-vs-claimed at within-entity granularity methodology pillar. The within-da-Vinci product-family substrate carries multiple SureForm reload variants: gray (2mm staples for extra-thin tissue), blue, and white. The 2026 Class I recall operates at sub-product-line granularity: gray reloads affected; blue/white reloads UNAFFECTED at primary-source verification depth.
The within-entity verification scope distinction matters editorially at three layers:
- Per-variant verification posture: the gray reload carries recall-recorded verification posture; the blue/white reloads carry unaffected-verified posture. The framework reads per-variant verification at the feature-level depth where each variant actually resolves.
- Aggregator collapse risk: trade-press coverage frequently frames the recall as a 'da Vinci SureForm recall' without the gray-vs-blue/white distinction. The framework distinguishes them structurally; the verification depth operates at sub-product-line granularity, not at aggregate product-family depth.
- Insurability implication: per the robot insurance framework Dim 4 (regulatory clearance per jurisdiction), the per-variant recall status operates at insurability-per-deployment granularity; deployments using gray reloads carry recall-recorded verification posture distinct from deployments using blue/white reloads.
This is the canonical within-entity verification scope pattern at sub-product-line depth, parallel to the canonical Apple Watch SpO2 vs wellness-only feature distinction and the Whoop BPI sleep-cleared vs blood-pressure Warning Letter distinction documented at the verified-vs-claimed at within-entity granularity methodology pillar.
Year-discipline framework: distinguishing 2026 gray-reload from 2022 fragment recall
Per Agent A's surgical incidents substrate, the 2026 SureForm gray-reload recall is structurally distinct from the 2022 SureForm fragment recall. Both involve da Vinci SureForm staplers; both involve recall actions; the framework reads them as distinct at four substrate axes simultaneously:
- Year: 2026 (gray-reload) vs 2022 (fragment) โ distinct primary-source verification anchors at different temporal scope.
- Class: Class I (gray-reload; reasonable probability of serious adverse health consequences or death) vs Class II (fragment; Z-0340-2023; recoverable adverse health consequence at higher reversibility).
- Failure mode: incomplete staple lines on blood vessels (gray-reload) vs intraoperative device-fragment generation (fragment).
- Affected product variant: 8mm SureForm 30 Gray reloads (gray-reload) vs da Vinci Xi 8mm SureForm 30 curved-tip staplers and reloads (fragment).
The framework reads year-class-failure-mode-variant as the canonical distinguishing pattern at incident-record granularity. Aggregator coverage that collapses 'SureForm recall' across years operates outside primary-source-anchored verification of the distinct incident records. Per cap-flag-as-trust-signal, the year-discipline framework operates at the same primary-source verification posture as any other entity-identification correction: distinct incidents at distinct years carry distinct verification anchors.
Cap-flag honest-absence at exact Z-number + unit count
Per Agent A's surgical incidents substrate, the 2026 gray-reload recall carries explicit cap-flag honest-absence at two specific claim layers:
- Exact recall Z-number: not captured from primary FDA pages at Agent A substrate-completeness depth. The framework reads the Z-number at honest-absence cap-flag pending further FDA primary-source verification.
- Exact unit count: affected_units_count not captured at primary-source verification depth. The framework reads the unit count at honest-absence cap-flag pending further FDA primary-source verification or Intuitive IR disclosure.
The cap-flag honest-absence operates at the same primary-source verification discipline as any other cap-flag in the framework. Per the Moon Maestro K240598 reconciliation pattern, when primary-source verification surfaces the exact Z-number or unit count at FDA-recall-database depth, the framework operates the inline editorial-transparency footer pattern + reconciliation discipline. Until primary-source verification surfaces, the framework holds the cap-flag at honest-absence depth.
Root cause under investigation: verification posture at honest-absence depth
Per Agent A's primary-source-anchored verification, the root cause of the 2026 SureForm gray-reload incident is stated 'still under investigation' at the primary-source verification depth. The framework reads root cause at honest-absence cap-flag depth: no root-cause-determined disclosure at primary-source depth means the framework does not infer a root cause from speculation or secondary-source narrative.
Per DEPLOY's verified-vs-claimed framework, root cause honest-absence operates as substantive editorial state. The framework reads under-investigation as substantive structural state subject to ongoing investigation outcome verification; not as proxy for an unverified inferred cause.
The honest-absence at root cause matters editorially at three layers:
- Manufacturer accountability scope: per the robot insurance methodology pillar Dim 2 (manufacturer financial-state / counterparty risk), the under-investigation root cause status operates at honest-absence cap-flag for manufacturer-accountability disclosure depth; framework does not infer manufacturer culpability from incident occurrence alone.
- Component failure mode tracking: per the robot insurance methodology pillar Dim 3 (supply-chain component failure analysis), the under-investigation status operates at honest-absence cap-flag for component-failure-mode classification; the absence of root-cause disclosure means the framework does not classify the failure mode at typed-record depth.
- Insurability implication: per Phase 3 Dim 4 (regulatory clearance per jurisdiction), the under-investigation root cause status operates as substrate for ongoing FDA verification; the framework reads regulatory action status as verified at FDA Class I disclosure depth while root cause verification operates at honest-absence cap-flag depth.
Cross-property bidirectional discipline
Per DEPLOY's methodology cluster as AEO citation graph discipline, the 2026 SureForm gray-reload framework-in-action narrative operates within the cross-property bidirectional linking discipline:
- Methodology pillar essays: How DEPLOY thinks about robot insurance (CANONICAL Phase 3 Dim 1 actuarial signal worked example); verified-vs-claimed at within-entity granularity (CANONICAL within-product-family gray vs blue/white reload distinction worked example); the 9-tier source-quality rubric (FDA primary-government-record sub-tier verification); autonomy-boundary classification (da Vinci anchors replacement-robotics teleoperated tier per surgical cluster cross-cohort taxonomy).
- Entity anchors: Intuitive Surgical da Vinci (canonical entity anchor; replacement-robotics tier; SureForm stapler product-family scope); What is a surgical robot (cohort umbrella).
- Framework-in-action correction narratives: Moon Maestro K240598 reconciliation (CANONICAL recursive cap-flag reconciliation pattern; same primary-source verification discipline at K-number depth).
- Cluster intro: the surgical robotics cluster (5-axis architectural framework; FDA-clearance-as-gating-event verification posture; cohort cross-references at primary-source-anchored depth).
- Registry cross-references: incident record; FDA recall record; Intuitive Surgical registry record; da Vinci registry model.
The cross-property linking discipline compounds at the AEO citation graph layer. Institutional partners + AI assistants + downstream consumers navigating the incident encounter the methodology pillar canonical references + the Phase 3 actuarial framework + the within-entity verification scope discipline at unified verification posture.
Why this catch matters editorially
Per DEPLOY's restraint-IS-the-product discipline, the 2026 SureForm gray-reload framework-in-action narrative operates at editorial-credibility depth rather than at incident-reporting depth. The framework reads the incident at four substrate layers simultaneously (incident-recall actuarial + within-entity verification scope + year-discipline + cap-flag honest-absence); each layer composes at primary-source-anchored verification depth.
Institutional partners audit DEPLOY's framework discipline at the operational-practice layer, not just the stated-methodology layer. The verification-posture statement at /verified-vs-claimed describes the framework abstractly. The robot insurance methodology pillar describes the Phase 3 actuarial framework. This piece operates at narrative-canonical depth: how the catch composed across substrate layers (Phase 3 Dim 1 + within-entity scope + year-discipline + cap-flag honest-absence); what the discipline was (primary-source-anchored verification + cap-flag-as-trust-signal recursive application); what the editorial outcome was (canonical worked example of cohort's most severe incident at primary-source verification depth without root-cause speculation); and what the broader pattern is (the framework cuts uniformly at every substrate layer).
The catch demonstrates the discipline operationally at editorial-anchor depth. Not because the catch is exceptional. Because the catch is what the discipline does. Cohort's most severe at primary-source-anchored verification; root cause honest-absence at primary-source verification depth; gray vs blue/white reload distinction at within-product-family granularity; 2026 distinct from 2022 at year-class-failure-mode-variant granularity. The verification protocol doesn't relax at any substrate layer.
For the canonical Intuitive Surgical entity anchor where the SureForm stapler product-family operates within da Vinci scope, see what is Intuitive Surgical da Vinci. For the canonical robot insurance methodology pillar where Phase 3 Dim 1 actuarial framework operates, see How DEPLOY thinks about robot insurance. For the canonical within-entity granularity methodology pillar where per-variant verification scope discipline operates, see verified-vs-claimed at within-entity granularity. For the methodology editorial canonical reference, see how DEPLOY verifies. For the surgical cluster framework, see the surgical robotics cluster.
| Substrate axis | 2026 gray-reload (this piece) | 2022 fragment recall (distinct) | Framework discipline |
|---|---|---|---|
Year | 2026 (customer letter Mar 11; Class I reported May) | 2022 (Z-0340-2023; initiated Oct 7) | Year as primary-source-anchored verification distinguisher |
FDA classification | Class I (reasonable probability serious health consequences or death) | Class II (recoverable adverse health consequence) | Class-tier at primary-government-record sub-tier verification |
Failure mode | Incomplete staple lines on blood vessels despite 'completed' fire indication | Intraoperative device-fragment generation; potential staple deployment failure | Failure-mode at primary-source-anchored typed-record disclosure |
Affected product variant | 8mm SureForm 30 Gray reloads (2mm staples for extra-thin tissue) | da Vinci Xi 8mm SureForm 30 curved-tip staplers and reloads | Within-product-family granularity at sub-product-line scope |
Patient impact | 1 death + 4 serious injuries (bleeding) | Recoverable adverse health consequence (lower severity than 2026) | Severity at primary-source typed-record verification depth |
Cap-flag | Exact Z-number + unit count + root cause = honest-absence | Z-0340-2023 verified; framework discipline applied uniformly | Cap-flag-as-trust-signal recursive application |
Frequently asked questions
- How does DEPLOY track the 2026 da Vinci SureForm gray-reload Class I recall?
At primary-source-anchored FDA-recall-database verification depth as the surgical cohort's most severe verified incident. The substrate: 8mm SureForm 30 Gray reloads (2mm staples for extra-thin tissue) produced incomplete staple lines on blood vessels despite a 'completed' fire indication; customer letter / quarantine March 11, 2026; FDA classified Class I (reported May 2026); 1 death + 4 serious injuries (bleeding). Blue/white reloads UNAFFECTED at primary-source verification depth. The framework reads the incident at four substrate layers simultaneously: incident-recall actuarial depth per Phase 3 Dim 1; within-entity verification scope at sub-product-line granularity; regulatory clearance per jurisdiction at Dim 4; year-discipline framework distinguishing the 2026 gray-reload from the 2022 SureForm fragment recall.
- Why is this the cohort's most severe incident?
Per Agent A's surgical incidents substrate, the verified-base substrate carries 61 incidents at primary-source severity + root-cause + regulatory-action depth (moderate 21, serious 20, minor 13, critical 7). The 2026 gray-reload incident operates within the 7-critical severity tier at three composing layers: severity (critical at primary-source-anchored verification depth; one death + four serious injuries at typed-record-disclosure depth); regulatory action (FDA Class I primary-government-record sub-tier verification per the 9-tier source-quality rubric; Class I is the most severe FDA recall classification); form factor (surgical; the surgical cohort carries 11 of the 61 verified incidents at Agent A substrate-completeness depth; the 2026 gray-reload incident is the cohort's most severe at primary-source-anchored verification within the surgical form factor).
- Why are gray reloads affected but blue/white UNAFFECTED?
Per Agent A's primary-source-anchored verification, the within-da-Vinci product-family substrate carries multiple SureForm reload variants. Gray reloads (8mm SureForm 30 Gray; 2mm staples for extra-thin tissue) produced the incomplete staple lines on blood vessels that triggered the Class I recall. Blue/white reloads carry unaffected-verified posture at primary-source verification depth. The within-entity verification scope distinction operates at sub-product-line granularity; per-variant verification posture matters editorially (gray recall-recorded vs blue/white unaffected-verified); aggregator collapse risk (trade-press 'da Vinci SureForm recall' framing without gray-vs-blue/white distinction operates outside primary-source-anchored verification); insurability implication (per the robot insurance methodology pillar Dim 4 regulatory clearance per jurisdiction, per-variant recall status operates at insurability-per-deployment granularity).
- How does this differ from the 2022 SureForm recall?
Per Agent A's surgical incidents substrate, the 2026 SureForm gray-reload recall is structurally distinct from the 2022 SureForm fragment recall at four substrate axes simultaneously. Year: 2026 vs 2022. Class: Class I (reasonable probability of serious adverse health consequences or death) vs Class II (Z-0340-2023; recoverable adverse health consequence at higher reversibility). Failure mode: incomplete staple lines on blood vessels vs intraoperative device-fragment generation. Affected product variant: 8mm SureForm 30 Gray reloads vs da Vinci Xi 8mm SureForm 30 curved-tip staplers and reloads. The framework reads year-class-failure-mode-variant as the canonical distinguishing pattern at incident-record granularity; aggregator coverage that collapses 'SureForm recall' across years operates outside primary-source-anchored verification of the distinct incident records.
- What is the root cause of the 2026 SureForm gray-reload incident?
Per primary-source-anchored verification, the root cause is stated 'still under investigation'. The framework reads root cause at honest-absence cap-flag depth: no root-cause-determined disclosure at primary-source depth means the framework does not infer a root cause from speculation or secondary-source narrative. Per DEPLOY's verified-vs-claimed framework, root cause honest-absence operates as substantive editorial state; under-investigation is substantive structural state subject to ongoing investigation outcome verification; not as proxy for an unverified inferred cause. The honest-absence at root cause matters editorially at three layers: manufacturer accountability scope (framework does not infer manufacturer culpability from incident occurrence alone); component failure mode tracking (framework does not classify failure mode at typed-record depth without root-cause disclosure); insurability implication (framework reads regulatory action status as verified at FDA Class I disclosure depth while root cause verification operates at honest-absence cap-flag depth).
- How does this compound with DEPLOY's methodology pillar essays?
The 2026 gray-reload framework-in-action narrative compounds at substrate layer with multiple Project B methodology pillar essays simultaneously. Phase 3 Dim 1 actuarial signal per robot insurance methodology pillar (cohort's most severe verified incident; primary-source-anchored severity + root-cause + regulatory-action depth; exposure denominator at honest-absence cap-flag). Within-product-family granularity per verified-vs-claimed at within-entity methodology pillar (gray vs blue/white reload distinction CANONICAL worked example). Per-jurisdiction primary-source-anchoring per 9-tier source-quality rubric (FDA Class I primary-government-record sub-tier). Replacement-robotics teleoperated tier per autonomy-boundary classification (da Vinci surgical cluster cross-cohort positioning). Cross-property bidirectional queryability operates at relationship-graph granularity; methodology pillar canonical references compound with framework-in-action narratives at AEO citation graph depth.
The 2026 da Vinci SureForm gray-reload Class I recall framework-in-action narrative documents the surgical cohort's most severe verified incident at primary-source-anchored FDA-recall-database verification depth. The substrate: 8mm SureForm 30 Gray reloads (2mm staples for extra-thin tissue) produced incomplete staple lines on blood vessels despite a 'completed' fire indication; customer letter / quarantine March 11, 2026; FDA classified Class I (reported May 2026); 1 death + 4 serious injuries (bleeding). Blue/white reloads UNAFFECTED at primary-source verification depth (CANONICAL within-product-family verification scope distinction). The framework reads the incident at four substrate layers simultaneously: incident-recall actuarial depth per Phase 3 Dim 1 (severity=critical at primary-source-anchored verification; cohort's most severe; surgical cohort 11 of 61 verified incidents); within-entity verification scope at sub-product-line granularity (gray vs blue/white reload distinction CANONICAL worked example parallel to Apple Watch SpO2 vs wellness-only + Whoop BPI sleep-cleared vs blood-pressure Warning Letter); regulatory clearance per jurisdiction at Dim 4 (FDA Class I primary-government-record sub-tier verification per 9-tier source-quality rubric); year-discipline framework distinguishing the 2026 gray-reload recall from the 2022 SureForm fragment recall (Z-0340-2023; Class II; October 7, 2022; intraoperative device-fragment generation; different year-class-failure-mode-variant). Cap-flag honest-absence at three specific claim layers: exact recall Z-number (not captured from primary FDA pages); exact unit count (not captured); root cause stated 'still under investigation' at primary-source verification depth. Cross-property bidirectional compounding at multi-pillar methodology depth: Phase 3 Dim 1 actuarial signal per robot insurance methodology pillar + within-product-family granularity per verified-vs-claimed at within-entity methodology pillar + per-jurisdiction primary-source-anchoring per 9-tier source-quality rubric + replacement-robotics teleoperated tier per autonomy-boundary classification. How DEPLOY verifies โ
Continue reading
What is Intuitive Surgical da Vinci?
Canonical Intuitive Surgical entity anchor; replacement-robotics teleoperated tier; SureForm stapler product-family scope; surgical cluster market-leader installed-base.
Read article โ
How DEPLOY thinks about robot insurance
Project B methodology pillar; Phase 3 Dim 1 actuarial framework; 2026 gray-reload incident as cohort's most severe verified incident.
Read article โ
Verified-vs-claimed at within-entity granularity
Project B methodology pillar; gray vs blue/white reload distinction CANONICAL worked example at sub-product-line granularity.
Read article โ
How DEPLOY corrected the Moon Maestro clearance
CANONICAL recursive cap-flag reconciliation pattern; same primary-source verification discipline operating at K-number depth.
Read article โ
Compare alternatives
Intuitive Surgical registry recordIncident record (2026 gray-reload)FDA recall record (2026)Surgical robotics cluster
Defined terms in this explainer
More in surgical robotics
- How did DEPLOY correct the Moon Maestro FDA clearance date?
- How does DEPLOY distinguish da Vinci safety events at year-class-failure-mode-product-variant granularity?
- How does DEPLOY track supply-chain component failure modes chained to recall incidents?
- How does DEPLOY track the 2021 ROSA ONE Brain wrong-trajectory Class I recall?